Why Salesforce Stock Is Surging Today

Salesforce Inc (NYSE: CRM) shares are trading higher Monday following reports activist investor Elliott Management took a multi-billion dollar stake in the cloud software company.

Salesforce Inc (NYSE:CRM) shares are trading higher Monday following reports activist investor Elliott Management took a multi-billion dollar stake in the cloud software company.

What Happened: According to a Wall Street Journal report citing people familiar with the matter, Elliot Management, one of the largest activists, has taken a sizeable position in Salesforce just weeks after the company announced plans to cut its workforce and close offices to manage costs. It’s not clear what the firm’s plans are for the company. 

“Salesforce is one of the preeminent software companies in the world, and having followed the company for nearly two decades, we have developed a deep respect for Marc Benioff and what he has built,” Jesse Cohn, managing partner at Elliott Management, reportedly said.

“We look forward to working constructively with Salesforce to realize the value befitting a company of its stature.”

Salesforce provides enterprise cloud computing solutions to companies of every size. In the company’s most recent earnings report, Salesforce guided for fourth-quarter revenue growth between 8% and 10%, down from 14% sequentially.

See Also: US Stocks Seem To Flatline As Traders Digest Friday’s Gains: Key Earnings To Dominate Sentiments This Week

CRM Price Action: Salesforce has a 52-week high of $234.49 and a 52-week low of $126.34.

The stock was up 4.71% at $158.39 at time of publication, according to Benzinga Pro.

Photo: courtesy of Salesforce.

Total
0
Shares
Related Posts
Read More

Novartis Announced Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya Dosing Regimen Patent

Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC's decision with the US Supreme Court.

NVS